Loading
A phase 2 trial of gemcitabine + nab-paclitaxel and nimotuzumab in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06938503 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 48 participants, started 2025-04-21 and due to reach its primary completion in 2028-04-25. Interventions recorded: AG regimen; Nimotuzumab. Conditions listed: Pancreatic Cancer, Adult. Primary outcome: overall survival (OS). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic cancer;". No results are recorded here; the registry entry is the source.
Shares Nimotuzumab, Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Irreversible electroporation (NanoKnife), Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.